Teva in Focus: New Therapeutic Entities - from Process to Product
19 Novembre 2013 - 4:03PM
Business Wire
Teva unveils new pipeline assets from the
NTE program of 2013 in the 2nd Teva R&D In-Focus
Webinar
- December 4th @ 8:00am Eastern Time
–
Developing new pipeline assets through the New Therapeutic
Entities (NTE) process, which was launched less than one year ago,
is a major element in Teva's strategy for growth. Join the Teva
In-Focus NTE Webinar on December 4th to learn more about some of
the product candidates that the NTE process has produced in
2013.
In the latest in the Teva In-Focus webinar series, Teva will
outline:
- The steps in the project concept
generation, evaluation and selection process
- A few of the projects that have been
selected for development
- The expected contributions of these
projects over the next few years
The Teva In-Focus NTE webinar will include an in-depth review of
certain key projects from the NTE program of 2013. It will outline
the global market and unmet needs for each. Highlight the approach
and technologies Teva is using to improve upon known molecules to
address these unmet needs. Finally, it will provide a clear picture
of the development plans and expected benefits for this will create
for clinicians, patients and Teva.
Dr. Michael Hayden, Teva’s President of Global R&D and Chief
Scientific Officer, will lead the webinar and will be joined by key
leaders from Teva’s NTE program.
A question and answer session will follow the presentation.
Webinar access details:
Meeting Title: Teva NTE WebinarMeeting Date:
December 4th, 2013Meeting Time: 8:00 AM [Eastern
Time]Duration: 1 Hour 30 MinutesWebcast
Link: http://www.media-server.com/m/p/m753rv5e
Dial-in details:
US Toll Free 1-866-318-8620International
1-617-399-5139Participant Passcode 92011346
About Teva
Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is a leading
global pharmaceutical company, committed to increasing access to
high-quality healthcare by developing, producing and marketing
affordable generic drugs as well as innovative and specialty
pharmaceuticals and active pharmaceutical ingredients.
Headquartered in Israel, Teva is the world's leading generic drug
maker, with a global product portfolio of more than 1,000 molecules
and a direct presence in about 60 countries. Teva's branded
businesses focus on CNS, oncology, pain, respiratory and women's
health therapeutic areas as well as biologics. Teva currently
employs approximately 46,000 people around the world and reached
$20.3 billion in net revenues in 2012.
Teva's Safe Harbor Statement under the U. S. Private
Securities Litigation Reform Act of 1995:
This release contains forward-looking statements, which express
the current beliefs and expectations of management. Such statements
are based on management’s current beliefs and expectations and
involve a number of known and unknown risks and uncertainties that
could cause our future results, performance or achievements to
differ significantly from the results, performance or achievements
expressed or implied by such forward-looking statements. Important
factors that could cause or contribute to such differences include
risks relating to: the ability to reduce operating expenses to the
extent and during the timeframe intended by our cost restructuring
program; our ability to develop and commercialize additional
pharmaceutical products, including our ability to develop,
manufacture, market and sell biopharmaceutical products,
competition for our innovative products, especially COPAXONE®
(including competition from innovative orally-administered
alternatives, as well as from potential purported generic
equivalents), competition for our generic products (including from
other pharmaceutical companies and as a result of increased
governmental pricing pressures), competition for our specialty
pharmaceutical businesses, our ability to achieve expected results
through our specialty, including innovative, R&D efforts, the
effectiveness of our patents and other protections for innovative
products, decreasing opportunities to obtain U.S. market
exclusivity for significant new generic products, our ability to
identify, consummate and successfully integrate acquisitions, the
effects of increased leverage as a result of recent acquisitions,
the extent to which any manufacturing or quality control problems
damage our reputation for high quality production and require
costly remediation, our potential exposure to product liability
claims to the extent not covered by insurance, increased government
scrutiny in both the U.S. and Europe of our agreements with brand
companies, potential liability for sales of generic products prior
to a final resolution of outstanding patent litigation, our
exposure to currency fluctuations and restrictions as well as
credit risks, the effects of reforms in healthcare regulation and
pharmaceutical pricing and reimbursement, any failures to comply
with complex Medicare and Medicaid reporting and payment
obligations, governmental investigations into sales and marketing
practices (particularly for our specialty pharmaceutical products),
uncertainties surrounding the legislative and regulatory pathways
for the registration and approval of biotechnology based products,
adverse effects of political or economical instability, corruption,
major hostilities or acts of terrorism on our significant worldwide
operations, interruptions in our supply chain or problems with our
information technology systems that adversely affect our complex
manufacturing processes, any failure to retain key personnel or to
attract additional executive and managerial talent, the impact of
continuing consolidation of our distributors and customers,
variations in patent laws that may adversely affect our ability to
manufacture our products in the most efficient manner, potentially
significant impairments of intangible assets and goodwill,
potential increases in tax liabilities, the termination or
expiration of governmental programs or tax benefits, environmental
risks and other factors that are discussed in our Annual Report on
Form 20-F for the year ended December 31, 2012 and in our other
filings with the U.S. Securities and Exchange Commission.
Forward-looking statements speak only as of the date on which they
are made and the Company undertakes no obligation to update or
revise any forward looking statement, whether as a result of new
information, future events or otherwise.
IR Contacts:United StatesKevin C. Mannix, 215-591-8912orUnited
StatesRan Meir, 215-591-3033orIsraelTomer Amitai, 972 (3)
926-7656orPR Contacts:IsraelIris Beck Codner, 972 (3)
926-7687orUnited StatesDenise Bradley, 215-591-8974
Teva Pharmaceutical Indu... (NYSE:TEVA)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Teva Pharmaceutical Indu... (NYSE:TEVA)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024